Multiple Sclerosis (MS) affects about 100,000 people in the UK, and is the commonest cause of neuro-disability in young adults. It is most prevalent in people aged 20 to 40 years, can occur in the very young and elderly, and is three times more common in women than men. Multiple treatments exist for the inflammatory stage of relapsing-remitting MS: but none alter the course of progressive MS.Research teams from Plymouth University Peninsula Schools of Medicine and Dentistry are in the vanguard of work in two areas: methods of measuring how people with MS feel and function (patient-reported outcome measures; PRO[M]S); and the evidence base underpinning cannabinoids as an MS treatment, and as a method to slow neurodegeneration.
The PROMS developed at Plymouth University under the leadership of Professor Jeremy Hobart has directly influenced clinical research, trials and drug licensing in MS and Alzheimer鈥檚 disease. The MS scales developed by this team are widely used by academics and commercial organisations in MS drug development and evaluation, and have resulted in new drugs being licensed. Some scales have been translated into over 60 languages. The specific measurement science methods used by this research group to construct instruments have been endorsed by the United States Food and Drug Administration, whom they have educated.
Said Professor Hobart: 鈥淲hen we study new treatments for diseases we track the treatment鈥檚 effects carefully. If we track people鈥榮 reports of how they feel and function we get a direct indicator of whether treatments are beneficial for people with the disease. PRO[M]s does this. But the measures must be good because of their critical role. Basically, they determine which new treatments doctors can prescribe, and how NHS money is spent. When poor quality measures are used the chances increase of concluding that good drugs don鈥檛 work. When that happens, people miss out on treatments that might help them. This is really important, more than people recognise. As I re-asserted in a paper in The Lancet in 2007, many measures used in clinical trials are not fit-for-purpose: the clinical trials are undermined, beneficial treatment effects will be missed. This is why we set out to develop good quality PRO measures for MS. For example, we developed a PRO measure of walking. It鈥檚 such an important daily activity for most people and in MS up to 85 per cent of people are walking disabled.鈥
The potential of cannabis/cannabinoids as a treatment for MS is supported anecdotally, but there has been a paucity of clinical trial evidence.
